## Sylvie Odent

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11340898/publications.pdf

Version: 2024-02-01

933264 1281743 1,619 10 10 11 citations h-index g-index papers 11 11 11 2648 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Mutations in the $\hat{I}^2$ -tubulin gene TUBB2B result in asymmetrical polymicrogyria. Nature Genetics, 2009, 41, 746-752.	9.4	330
2	BBS10 encodes a vertebrate-specific chaperonin-like protein and is a major BBS locus. Nature Genetics, 2006, 38, 521-524.	9.4	259
3	Large spectrum of lissencephaly and pachygyria phenotypes resulting from de novo missense mutations in tubulin alpha 1A (TUBA1A). Human Mutation, 2007, 28, 1055-1064.	1.1	213
4	Comparison of Clinical Presentations and Outcomes Between Patients With <i>TGFBR2</i> and <i>FBN1</i> Mutations in Marfan Syndrome and Related Disorders. Circulation, 2009, 120, 2541-2549.	1.6	203
5	Mutations in the TGF $\hat{I}^2$ Binding-Protein-Like Domain 5 of FBN1 Are Responsible for Acromicric and Geleophysic Dysplasias. American Journal of Human Genetics, 2011, 89, 7-14.	2.6	199
6	Marfan Sartan: a randomized, double-blind, placebo-controlled trial. European Heart Journal, 2015, 36, 2160-2166.	1.0	179
7	International Registry of Patients Carrying <i>TGFBR1</i> or <i>TGFBR2</i> Mutations. Circulation: Cardiovascular Genetics, 2016, 9, 548-558.	5.1	145
8	Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome. Archives of Cardiovascular Diseases, 2010, 103, 317-325.	0.7	68
9	Incidence of cardiovascular events and risk markers in a prospective study of children diagnosed with Marfan syndrome. Archives of Cardiovascular Diseases, 2020, 113, 40-49.	0.7	12
10	Orthopedics management of acromicric dysplasia: Follow up of nine patients. American Journal of Medical Genetics, Part A, 2014, 164, 331-337.	0.7	10